Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

This study has been completed.

First Received: December 19, 2006 No Changes Posted

Sponsor:	Walter Reed Army Medical Center
Information provided by:	Walter Reed Army Medical Center
ClinicalTrials.gov Identifier:	NCT00413751

Purpose

The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.

Condition	Intervention
Healthy	Drug: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)

Study Type:	Observational
Study Design:	Longitudinal, Convenience Sample, Prospective Study

Resource links provided by NLM:

Drug Information available for: Brimonidine Brimonidine tartrate

U.S. FDA Resources

Further study details as provided by Walter Reed Army Medical Center:

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	18 Years to 50 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better.

Exclusion Criteria:

Patients not meeting above stated age criteria
Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study)
History of serious ocular, neurological, cardiovascular disease
History of severe systemic disease
History of arrhythmias or high blood pressure
Patients currently taking any type of ocular or systemic medications except multivitamins.
Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00413751

Locations

United States, District of Columbia
Walter Reed Army Medical Center
Washington, District of Columbia, United States, 20307

Sponsors and Collaborators

Walter Reed Army Medical Center

Investigators

Principal Investigator:

KRAIG S. BOWER, MD

Walter Reed Army Medical Center

More Information

No publications provided

Study ID Numbers:	WRAMC WU #03-23004
Study First Received:	December 19, 2006
Last Updated:	December 19, 2006
ClinicalTrials.gov Identifier:	NCT00413751 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by Walter Reed Army Medical Center:

Large pupils rendering night vision difficulties such as haloes, glare, and monocular diplopia

Additional relevant MeSH terms:

Neurotransmitter Agents
Adrenergic alpha-Agonists
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Therapeutic Uses
Physiological Effects of Drugs

Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions
Adrenergic Agonists
Brimonidine

ClinicalTrials.gov processed this record on February 08, 2010